PSS3 TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGANGANFORT AND TRAVATAN-DUOTRAV- AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

Oct 1, 2009, 00:00
10.1016/S1098-3015(10)75240-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)75240-2/fulltext
Title : PSS3 TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGANGANFORT AND TRAVATAN-DUOTRAV- AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75240-2&doi=10.1016/S1098-3015(10)75240-2
First page :
Section Title :
Open access? : No
Section Order : 1166
Categories :
Tags :
Regions :
ViH Article Tags :